Search research articles
Contact Us
Filters
Showing results (21-30 of 277) with videos related to
Page
of 28
Sort By:
Cell Reports
|
March 7, 2019
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell, Seth A Wander, Tanvi Visal, et al.
Investigational New Drugs
|
July 12, 2021
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
Crystal S Denlinger, Vicki L Keedy, Victor Moyo, et al.
Oncogene
|
January 28, 2005
Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice
Mirna Lechpammer, Xiangjun Xu, F Henry Ellis, et al.
Cancer Research
|
August 4, 2006
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function
Farid Gizatullin, Yao Yao, Victor Kung, et al.
Investigational New Drugs
|
January 24, 2017
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
James M Cleary, Lee S Rosen, Kenichiro Yoshida, et al.
JCO Precision Oncology
|
October 21, 2024
Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology
Massimiliano Russo, Francesco Mariani, James M Cleary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2014
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors
Geoffrey I Shapiro, Eunice Kwak, Bruce J Dezube, et al.
Future Oncology (London, England)
|
February 19, 2013
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
John Marshall, Geoffrey I Shapiro, Martina Uttenreuther-Fischer, et al.
Clinical Lung Cancer
|
July 16, 2008
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer
Saby George, Basil S Kasimis, Janet Cogswell, et al.
Nature Reviews. Drug Discovery
|
October 6, 2022
Targeting replication stress in cancer therapy
Alexandre André B A da Costa, Dipanjan Chowdhury, Geoffrey I Shapiro, et al.
Page
of 28
Search research articles
Search
Showing results (21-30 of 277) with videos related to
Sort By:
Page
of 28
Cell Reports
|
March 7, 2019
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell, Seth A Wander, Tanvi Visal, et al.
Investigational New Drugs
|
July 12, 2021
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
Crystal S Denlinger, Vicki L Keedy, Victor Moyo, et al.
Oncogene
|
January 28, 2005
Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice
Mirna Lechpammer, Xiangjun Xu, F Henry Ellis, et al.
Cancer Research
|
August 4, 2006
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function
Farid Gizatullin, Yao Yao, Victor Kung, et al.
Investigational New Drugs
|
January 24, 2017
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
James M Cleary, Lee S Rosen, Kenichiro Yoshida, et al.
JCO Precision Oncology
|
October 21, 2024
Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology
Massimiliano Russo, Francesco Mariani, James M Cleary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2014
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors
Geoffrey I Shapiro, Eunice Kwak, Bruce J Dezube, et al.
Future Oncology (London, England)
|
February 19, 2013
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
John Marshall, Geoffrey I Shapiro, Martina Uttenreuther-Fischer, et al.
Clinical Lung Cancer
|
July 16, 2008
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer
Saby George, Basil S Kasimis, Janet Cogswell, et al.
Nature Reviews. Drug Discovery
|
October 6, 2022
Targeting replication stress in cancer therapy
Alexandre André B A da Costa, Dipanjan Chowdhury, Geoffrey I Shapiro, et al.
Page
of 28